Immunome (NASDAQ:IMNM) Insider Jack Higgins Sells 13,200 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) insider Jack Higgins sold 13,200 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the sale, the insider owned 65,050 shares in the company, valued at approximately $1,647,066. This trade represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Price Performance

Shares of IMNM stock opened at $23.95 on Wednesday. The firm has a market cap of $2.72 billion, a PE ratio of -9.47 and a beta of 2.13. The company has a 50-day moving average of $25.33 and a two-hundred day moving average of $22.74. Immunome, Inc. has a 1-year low of $8.93 and a 1-year high of $30.06.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). Sell-side analysts anticipate that Immunome, Inc. will post -2.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunome

Institutional investors have recently modified their holdings of the business. Allworth Financial LP acquired a new stake in Immunome during the second quarter worth approximately $25,000. Integrated Wealth Concepts LLC acquired a new position in shares of Immunome in the 2nd quarter valued at $27,000. Assetmark Inc. boosted its holdings in shares of Immunome by 46.6% in the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after buying an additional 1,442 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Immunome by 0.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 188,636 shares of the company’s stock valued at $3,997,000 after buying an additional 1,625 shares during the last quarter. Finally, KBC Group NV purchased a new position in shares of Immunome in the 1st quarter valued at $60,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on IMNM shares. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Barclays began coverage on Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective on the stock. Citigroup reissued a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Truist Financial raised their target price on Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Immunome in a research report on Thursday, September 10th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.64.

Immunome Company Profile

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.

Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.